Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

LNTH

Lantheus Holdings, Inc.

In Vitro & In Vivo Diagnostic Substances · SIC 2835CIK 1521036Held by 6 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$1.54B
Net Income FY2025
$0.23B
EPS (Basic, as reported)
$3.46
Net Margin FY2025
15.2%
ROE FY2025
21.4%
Total Equity
$1.09B
Shares Out
65M
Business description

Lantheus Holdings, Inc. — In Vitro & In Vivo Diagnostic Substances. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2013–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 302 → 1,542 +19.9% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue3023313433473394259351,2961,5341,542
Cost of revenue(164)(169)(168)(173)(201)(238)(353)(587)(546)(600)
Gross profit138162175175139188582710988942
Research & development(12)(18)(17)(20)(33)(45)(312)(78)(168)(177)
Selling & marketing(37)(42)(43)(42)(41)(68)(100)(142)(178)(179)
General & administrative(39)(50)(50)(61)(69)(150)(134)(125)(194)(275)
Total operating expenses—(110)(110)(123)(143)—————
Operating income57526452(4)(61)36365457311
Interest expense(27)(18)(17)(14)(9)(8)(7)(20)(20)(20)
Interest & investment income—0010032037—
Other income (expense), net092(6)2(7)(2)663731
Pre-tax income28405029(11)(75)27411431314
Income tax expense(2)(84)(9)(3)(2)(4)(1)(84)(119)(80)
Net income271234132(13)(71)28327312234
EPS — basic$0.84$3.31$1.06$0.81($0.25)($1.06)$0.41$4.79$4.52$3.46
EPS — diluted$0.82$3.17$1.03$0.79($0.25)($1.06)$0.40$4.65$4.36$3.41
Shares outstanding — basic (M)32373839546768686967
Shares outstanding — diluted (M)33394040546771707268

Showing the latest 10 of 13 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.